About Us
Company Information
Pharma Equity Group is a listed company on the Nasdaq Copenhagen Stock Exchange, with a focus on early investment in innovative life science companies (in or before phase 2) that develop technologies and therapies that have the potential to improve human health and quality of life. The team consists of experienced professionals with a background in the life science industry as well as in investment and business development. In addition, Pharma Equity Group has a strong network of industry partners and advisors.
Our team consists of experienced professionals with backgrounds in the life science industry, as well as in investment and business development. We have a strong network of industry partners and advisors and are committed to collaborating with our portfolio companies to help them achieve their goals.
Investment Focus: We specialize in early-stage investments in biotechnology (Prior to phase 2). We are particularly interested in companies that are developing novel therapies for unmet medical needs.
Our portfolio currently includes Reponex Pharmaceuticals A/S. Reponex Pharmaceuticals A/S is a clinical-stage biopharmaceutical company dedicated to the development of novel, effective treatments for diseases that have significant patient and social impact for which current therapy is lacking or in need of improvement. The strategy creates a cost-efficient and flexible way to create relevant humane ressources fast, which is considered a key factor and drives success.
History
Pharma Equity Group, formerly Blue Vision, is listed on the main list on the Nasdaq Copenhagen Stock Exchange.
On 5 April 2022, Pharma Equity Group launched a conditional takeover offer to the shareholders of Reponex Pharmaceuticals A/S (“Reponex”).
On 27 February 2023, the transaction with Reponex was approved by The Danish Financial Supervisory Authority and Nasdaq Copenhagen.
First trading day for newly issued shares on Nasdaq Copenhagen is 28th of March 2023.
Board of Directors
Claus Abildstrøm
Chairman of the Board of Directors
- FANUM A/S, bestyrelsesmedlem
- KOLIND A/S, bestyrelsesmedlem
- CAAB CONSULTING ApS, direktør
- PII A/S, bestyrelsesmedlem
- DANDERS & MORE ADVOKATPARTNERSELSKAB, bestyrelsesformand
- DM KOMPLEMENTAR ADVOKATANPARTSSELSKAB, bestyrelsesmedlem
- KOLIND INVEST A/S, bestyrelsesmedlem
- AB A/S, bestyrelsesmedlem
- NORDHOLM ApS, bestyrelsesmedlem
- SPC HOLDINGS A/S, bestyrelsesmedlem
Peter Mørch Eriksen
Board Member
- BBA Management Accounting, Diploma in Economics
- Executive leader with a proven track record of successful restructuring of international companies.
- Several years creating strategic focus and driving growth in complex and technology-intensive industries.
- Extensive experience with IPOs and capital market activities.
- Broad board experience in life sciences.
Future Committees
To support the Board in its duties, the Board will establish and appoint an Audit Committee, a Remuneration Committee, a Nomination Committee and a Business, Research and Development Committee. These committees will be charged with reviewing issues pertaining to their respective fields that are due to be considered at board meetings.
Meetings will be held to a minimum of 4 meetings per year or as often as requested by a member of the Committee or by the Company’s External auditor according to a specific event/challenge. The Committee only passes resolutions where recommendations are to be made to the Board of Directors.
The Committee has no independent decision-making power. All resolutions by the Committee must be passed by a simple majority of votes. Minutes of all meetings of the Audit Committee must be prepared at the latest 5 days after the meeting. The Committee’s nominations and recommendations to the Board of Directors must be set out clearly in the minutes, including their reasons.
Audit Committee
The Audit Committee is expected to be established with the purpose of assisting the Board of Directors with the monitoring of the financial reporting process, the statutory audit of the Company’s financial reports (including the process for presentation of accounts), internal control and risk management systems and the Company’s whistleblowing procedures and complaints. The Audit Committee shall also assess the external auditor’s independence and provision of services and the procedure for the election of the external auditor, and annually consider whether there is a need for an internal audit and if so, submit a recommendation to the Board of Directors in this respect including recommendations regarding the appointment, employment and dismissal of the chairman of any internal audit and the budget of the internal audit. The Audit Committee is expected to comply with the Danish Corporate Governance Recommendations Sections 3.4.2 and 3.4.3.
The purpose of the Audit Committee is to
-
Supervise the Company’s audit process, financial reporting process, risk management and security matters
-
Ensure the Company’s compliance with laws and regulations
-
Ensure the external auditor’s independence from the Company
-
Assessing internal control and risk management systems
The assignments of the Audit Committee are, among others, to supervise and monitor the following areas:
-
The financial reporting processes
-
To ensure that the financial information presented in the Pharma Equity Group’s annual and interim financial reports provides the basis and correctness of financial information, which can make basis for existing and future shareholders’ decision-making, regarding investment in the current and future companies in the portfolio.
-
To ensure a high degree of efficiency in the financial reporting processes.
-
To assess and if necessary, investigate Management’s actions and assessments for the annual and interim financial reporting before they are submitted to the Board of Directors.
-
Review assessment and explanation of the central conclusions in the annual financial reports, interim reports and forecast, including drafts of the board’s report on the same reports prior to the board’s review.
-
Review and assessments in relation to internal control and risk management systems – prior to the board’s review.
-
-
The external audits
-
To make a critical assessment of the independence, objectivity, and competence of the external auditors in relation to, among others, audit and supply of additional services to the Company.
-
Review and assess the draft of the audit protocol with the external auditors.
-
Review of the external auditors’ audit plan and review of the financial departments’ plan for finalizing the financial reports.
-
To submit recommendations to the Board of Directors for its recommendation to the general meeting on the appointment of external auditors.
-
-
Investment and financing policies
-
Control and monitoring of the investment- and financing policies and future strategies, including the degree of debt financing and the underlying factors such as interest rate risk and refinancing risk as well as assessment of the financial reserves.
-
-
The internal control and risk management systems
-
Continuous monitoring of the company’s internal control and risk management systems and procedures.
-
Nomination and Remuneration Committee
The Nomination and Remuneration Committee has as its objective, to improve the quality of the work of the Board of Directors by contributing to the preparation of the basis for the Board’s decisions regarding nomination and appointments of new members of the Board of Directors and the Executive management.
The Nomination Committee is expected to comply with the Danish Corporate Governance Recommendations Sections 3.4.2 and 3.4.5.
The purpose of the Nomination and Remuneration Committee is to assist with:
The nomination and appointment of members of the Board of Directors and Executive Management
Ensure that the Board of Directors and the Executive Management always have the required qualifications and experience
The conduct of regular evaluations of the Board of Directors’ and the Executive Management’s performance; and d) the drawing up, implementation and pursuit of the remuneration policy for members of the Board of Directors and the Executive Management.
The duties of the Nomination and Remuneration Committee are among others to supervise and monitor the following areas:
Recommendations to the Board of Directors on the pay and remuneration policy applicable to the Board of Directors and Executive Management, including general guidelines on incentive pay.
Proposals for the remuneration of the Board of Directors and Executive Board and to ensure that the remuneration is in accordance with the Company’s pay and remuneration policy.
Monitor the information in the annual report about remuneration
Assessment of the Board of Directors structure, size, composition, and performance, and recommend any changes to the Board of Directors.
The committee must also assess board members’ qualifications, knowledge and experience and report its assessment to the Board of Directors.
The Business, Research and Development Committee
The committee is expected to be established to assist the Board of Directors in monitoring and reviewing the company’s research, technologies, products, pipeline, clinical trials, supply chain management and business strategies.
The Business, Research and Development Committee is expected to consist of the following members: [Mette Zacho as chairman of the committee and Peter M. Eriksen as member].
The Committee has as its objective to improve the Board of Directors decision making according to make the optimal business-, research- and development decisions as well as a future strategy for the same areas, for the company.
The purpose of the Business, Research and Development Committee is to assist with:
-
Assisting the Board of Directors and Executive Management in reviewing and assessing the Company’s research and development (“R&D”) programs.
-
Assisting with the Company’s strategy and investment in R&D programs
The duties of the Research and Development Committee shall, in any case, include:
-
Reviewing and assessing the Company’s R&D programs and strategies, with the Research and Development Committee Chairperson playing a day-to-day role providing input on key aspects of such R&D programs
-
Monitoring and overseeing the Company’s progress in achieving R&D goals and objectives, and making recommendations to the Supervisory Board on modifications to the Company’s R&D goals and objectives.
-
Performing strategic reviews of the Company’s key R&D programs as well as the scientific and R&D aspects of licensing, strategic partnerships, and acquisition or divestiture transactions.
-
Reviewing the company’s scientific publication and communications plan
-
Reviewing and assessing the Company’s intellectual property portfolio and strategy
-
Evaluating and challenging the effectiveness and competitiveness of the research and development endeavors of the Company
-
Overseeing management’s exercise of its responsibility to assess and manage risks associated with the Company’s R&D programs and regulatory matters
-
Identifying and reporting to the Supervisory Board on significant emerging science and technology issues and trends that may impact the Company
-
Serving as a resource for management to consult on any such topics regarding scientific and regulatory matters as reasonably requested
-
Selecting, retaining, and supervising any advisors as the Research and Development Committee deems necessary, in its discretion, to fulfill its mandates under these terms of reference, and compensating, at the expense of the Company, such advisors.
Executive Management Team
Connect with us
Pharma Equity Group
Slotsmarken 18, 2.th.
DK-2970 Hørsholm
Denmark
Contact us at info@pharmaequitygroup.com